Precision medicine startup partners with Korean firm
Wauwatosa-based precision medicine company RPRD Diagnostics LLC has formed a strategic partnership with South Korean biotechnology firm Orient Bio Inc. on a trade mission to Korea. RPRD stands for Right Patient Right Drug, and the company focuses on helping doctors find the safest drug for a patient and reduce negative drug reactions. Orient Bio, founded in 1959, produces and supplies catalog products for the biotechnology industry, including animal models, laboratory supplies and medical equipment. It also provides pre-clinical services for drug development, including genetic testing. The companies signed a memorandum of understanding in Seoul to expand RPRD’s pharmacogenetics testing services into new markets, and for Orient Bio to diversify into precision medicine and clinical pharmacogenetics. RPRD recently launched CNT Panel, which is highly relevant for patients of East Asian ethnicity who may receive thiopurine drug treatment, prescribed for patients with leukemia in addition to other diseases.